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COMMENTARY

Metastatic deaths in retinoblastoma
patients treated with intraarterial chemotherapy
(ophthalmic artery chemosurgery) worldwide
David H. Abramson1,2* , Carol L. Shields3, Pascal Jabbour4, Luiz Fernando Teixeira5,
José Roberto Falco Fonseca6, Marcio Chaves Pedro Marques7, Francis L. Munier8, Francesco Puccinelli9,
Theodora Hadjistilianou10, Sandra Bracco11, Guillermo Chantada12, Alejandro Ceciliano13 and Y. Pierre Gobin14

Abstract
Background: Ophthalmic artery chemosurgery [OAC, intra-arterial chemotherapy (IAC)] was introduced in 2006 as
treatment modality for intraocular retinoblastoma. The purpose of this commentary is to retrospectively review the
incidence of metastatic deaths in retinoblastoma patients treated with OAC worldwide over a 10 year period. Retrospective data regarding metastatic deaths was collected from six international retinoblastoma centers (New York City
USA, Philadelphia USA, Sao Paulo Brazil, Siena Italy, Lausanne Switzerland and Buenos Aires Argentina). All retinoblastoma patients from these centers (naive and recurrent, unilateral and bilateral) treated with OAC/IAC since 2006 have
been included in this study. Data regarding number of patients, number of OAC/IAC infusions, number unilateral and
bilateral, number treated for naive disease or salvage and number of metastatic deaths have been assessed. Over
a 10-year period of time 1139 patients received OAC/IAC for 4396 infusions. At last follow-up there were only three
metastatic deaths (all treated in Buenos Aires).
Conclusion: The current survey assessed the recorded risk of metastatic deaths in six retinoblastoma centers worldwide in children with retinoblastoma (unilateral or bilateral) treated with OAC/IAC as primary or secondary therapy.
Overall, the observed risk for metastatic deaths from retinoblastoma was <1% in OAC/IAC treated children.
Keywords: Intra-arterial (intrarterial) chemotherapy (IAC), Metastatic death, Ophthalmic artery chemosurgery (OAC),
Retinoblastoma (Rb), Melphalan
Background
For more than 100 years, ocular oncologists have been
perfecting and attempting to find better alternatives
to enucleation for management of intraocular retinoblastoma. Small tumors without vitreous or subretinal
seeding have been effectively treated with laser photocoagulation, thermotherapy, cryotherapy or brachytherapy
without compromising patient survival from metastatic
disease [1]. As far back as 1903 and continuing for almost
90 years, external beam radiotherapy was the only way
to salvage eyes with advanced intraocular disease [2].
*Correspondence: abramsod@mskcc.org
1
Department of Surgery, Memorial Sloan Kettering Cancer Center, New
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Full list of author information is available at the end of the article

While there were no randomized trials comparing radiation to enucleation, it was universally recognized that
conservative (non-enucleation) therapies lead to similar rates of metastatic death. In the 1990s, radiation was
abandoned because of its impact on the development of
second non-ocular cancers (which caused more deaths
than primary retinoblastoma) [3] and was replaced
with systemic chemotherapy [4]. In 1996, several papers
described patients managed with systemic chemotherapy
(with focal consolidation treatments) and they did not
appear to have an increase in metastatic deaths (againno randomized trials were performed) but difficulty with
tumor control for advanced disease with this technique
lead to the development of intra-arterial chemotherapy [IAC, ophthalmic artery chemosurgery (OAC)] for
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advanced retinoblastoma. In some centers using IAC/
OAC, the enucleation rate has now dropped to 5% [5],
but some authors have questioned if successful salvage of
these eyes occurs with an increase in metastatic deaths
from retinoblastoma [6]. Our six centers from the USA,
Europe and Latin America have had extensive experience
over a 10-year period with OAC/IAC and collaborated
in the investigation of this query to report on the risk
for metastatic deaths from retinoblastoma in children
treated with IAC/OAC.

Survey
A retrospective survey of all patients treated with OAC/
IAC between May 2006 and November 1, 2016 from six
Rb centers was performed. Metastatic death from retinoblastoma was reported in addition to tumor laterality, number of cases treated with OAC/IAC, number
of infusions delivered in each center and whether the
patients received OAC/IAC as primary treatment (naïve)
or secondary (after prior systemic chemotherapy and or
radiotherapy). Each center used similar technique with
combinations of Melphalan, Topotecan and Carboplatin,
but there were minor variations in medication combinations and number of cycles as this was a retrospective
analysis.
Between May 1, 2006 and November 1, 2016, our six
centers treated 1177 eyes of 1139 patients with 4396 separate OAC/IAC infusions. There were 781 unilateral and
358 bilateral cases. There were 464 (39%) eyes that were
naïve and 713 (61%) treated after prior systemic chemotherapy and/or radiation. Of these 1139 patients, there
were 3 (<1%) who died from metastatic retinoblastoma
(Table 1).
Discussion
Ophthalmic artery chemosurgery (OAC)/intra-arterial
chemotherapy (IAC) has become an important tool for
intraocular retinoblastoma management. This technique
was first performed by Reese et al. more than 60 years
ago after delivering a nitrogen mustard derivative by
direct puncture of the carotid artery. Despite a “dramatic”
response, this strategy was abandoned because of complications (including one death from carotid bleeding)
and one death from neutropenia. Reese never reported
on metastatic deaths in the 42 patients with retinoblastoma managed with carotid artery infusion.
Table 1 Summary data from 6 centers of all patients treated
with OAC between May 2006 and November 1, 2016
Patients

Infusions Uni/bilateral

First line
(#eyes)

Salvage
(# eyes)

Metastatic
deaths

1139

4396

464

713

3

781/358

Beginning more than 40 years ago, the Japanese perfected a technique they called “selective ophthalmic
artery infusion (SOAI)” of chemotherapy using Melphalan, a powerful alkylating agent that they had in vitro
determined was the most potent drug available for retinoblastoma. They reported on tumor control in a cohort of
343 patients treated with several methods and found metastatic deaths in 8, 5 with metastases and 3 with direct
or indirect extension into the central nervous system
and death [7]. Unfortunately, it is impossible to know the
exact treatment each child received because that report
combined hundreds of retinoblastoma cases treated with
external beam radiation, multiagent systemic chemotherapy, intravitreal chemotherapy (Melphalan) and hyperthermia in addition to SOAI, with approximately 50% of
these patients having all of the above treatments. Despite
this, the authors compared established death rates from
retinoblastoma in Japan and concluded that there was
no increase in deaths attributable to SOAI. The Japanese
study cannot be directly compared to the current survey
since follow-up is much more long term.
The modern intra-arterial approach was introduced
by two of us (DHA, YPG) in New York in May, 2006 [8].
Since that time it has been taught and adopted by nearly
all the major retinoblastoma sites worldwide [9–11], and
in a recent published worldwide survey chosen as the
first line approach for unilateral advanced retinoblastoma
[12]. Several major retinoblastoma centers employ OAC/
IAC for both naive and failed advanced eyes and in select
cases where macula tumors threaten vision for both unilateral and bilateral disease. While differences in choosing indications for OAC/IAC exist, the technique, drugs,
doses, frequency and catheters are generally the same
in all centers [9]. With time and experience, we have
achieved an eye salvage rate that improves with experience and now only 5–6% of all eyes with retinoblastoma
are primarily enucleated as a result of using first line
OAC/IAC and of those eyes treated 95% are retained [5,
13]. The frequency of metastatic deaths in OAC treated
children has been reported by many centers worldwide
and a year ago our centers in New York, Philadelphia,
Argentina and Switzerland reported on 634 cases with
only one metastatic death [9].
A recent publication (from authors who had never done
the procedure) has raised the question about metastatic
deaths [6]. These authors also questioned if leaving an eye
in with higher risk pathological features might preclude
giving systemic chemotherapy and therefore compromise
survival. Since OAC/IAC has become a transformative
option for the management of retinoblastoma from the
time of radiation, we decided to update our collective
experience and include two additional experienced centers-from Italy and Brazil to expand our knowledge base.
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There were no metastatic deaths from the two USA centers, two European centers or Brazil but 3 from the center
in Argentina and they are instructive.
Case 1 Bilateral retinoblastoma with a positive family history. The child was initially treated with systemic
chemotherapy and progressed and received OAC. After
progression intravitreal chemotherapy was given and
then a second round of systemic chemotherapy which
also failed. The family refused enucleation. Orbital invasion and metastasis with death ensued.
Case 2 Bilateral retinoblastoma with a positive family
history. One eye (International Classification E) refused
enucleation and then refused systemic chemotherapy.
The child was given OAC/IAC while social services
worked to get consent for enucleation. Enucleation eventually performed and demonstrated scleral involvement
and post laminar invasion. Family did not return for
follow-up and then developed orbital disease that was
treated with systemic chemotherapy but died after a CNS
relapse.
Case 3 Bilateral retinoblastoma with a positive family history. The child was initially treated with systemic
chemotherapy and external beam irradiation. Because
of progressive disease enucleation recommended but
refused so OAC/IAC given. The disease progressed after
treatment and enucleation was performed which showed
disease at the cut margin of the optic nerve. Orbital and
CNS invasion developed and later death.
Thus two of the deaths occurred in eyes previously
treated with combinations of systemic chemotherapy
and external beam irradiation and all deaths (2.6% of the
patients treated in Argentina) occurred in families refusing enucleation. This is comparable to the previously
reported experience in the same hospital in the pre-OAC
era (2.3%) [14]. Refusal of enucleation occurs more frequently in less developed countries [15].
This report summarizes the 10-year experience from
large retinoblastoma centers with experience with OAC/
IAC. Although the centers do not collaborate on a prospective trial algorithm they are all using the same technique, doses, drugs and catheters introduced by us at
Memorial Sloan Kettering Cancer Center and have all
independently (and collectively) reported similar high
ocular success rates. All metastatic deaths occurred in
the Argentinian cohort and followed refusal of enucleation or poor follow up.
The finding that metastatic deaths from retinoblastoma
are rare in patients treated with OAC/IAC is reassuring
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as this technique allows eyes that were previously enucleated worldwide to be salvaged.

Conclusion
This retrospective survey reports on the incidence of
metastatic deaths in retinoblastoma patients managed
OAC/IAC. Over a 10-year period, children with retinoblastoma (unilateral or bilateral) treated with OAC/IAC
as primary or secondary therapy showed <1% risk for
metastatic deaths from retinoblastoma.
Abbreviations
OAC: ophthalmic artery chemosurgery; IAC: intra-arterial chemotherapy; Rb:
retinoblastoma.
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